TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors. TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.
The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138. For full details, see the full press release.
The results are significant because TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis, in patients with advanced solid tumors who have already undergone prior treatment. Demonstrating a clean safety profile and early signs of disease stabilization at this stage could accelerate the program’s path toward later-phase testing, where efficacy will be more rigorously assessed. For investors, the data offer a key de-risking milestone for TransCode Therapeutics (NASDAQ: RNAZ), and the company directs investors to its newsroom at https://ibn.fm/RNAZ for the latest updates.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
